Branchburg, NJ) by 40 thermocycles of 94°C for 1 minute, 60°C for 1 minute and 72°C for 1 minute. The PDE PCR assay products were as follows with oligonucleotide sequences given 5'->3': Human PDE1B1 (Genbank accession # U56976) was 430 bp (1<sup>st</sup> base 1660; sense = GTC TTC ATT GAG TCC AAA GTG (SEQ ID NO.:1), antisense = GAC CTG CCA GCT AAG ATC TGG (SEQ ID NO.:2)). Human PDE3A (cGIP1, HSPDE3B) (X95520) was 340 bp (1st base 2999, sense = GTA ACT CCT ATG ATG CTG CTG G (SEQ ID NO.:3), antisense = CTA TTC CTC TTC ATC TGC CTC (SEQ ID NO.:4)). Of note, these PDE3 PCR oligonucleotides are selective for the human cGIP1 PDE, homologous to rat PDE3A, as the amplified sequence has only 50% nucleotide homology to the cardiac/platelet form of human PDE3 (cGIP2). Human PDE4A (M37744) was 461 bp (1st 1819, sense = GGA GGA AGA AAT ATC AAT GGC CC (SEQ ID NO.:5), antisense = GAT GTG TCC TCC CCA AAT GTC (SEQ ID NO.:6)). Human PDE4B (L20966) was 479 bp (1<sup>st</sup> bp 2213, sense = ATT CTG AAG GAC CTG AGA AGG (SEQ ID NO.:7), antisense = CAG TGA GTT CAG TCA CTG TCG (SEQ ID NO.:8)). For hybridization to Northern blots, these PCR products were subcloned into a plasmid vector (pCRII, Invitrogen, Carlsbad, CA) and subsequently utilized for PCR-based amplification of a32P dATP-labelled probes.

## REMARKS

Attached hereto is an Appendix showing the changes made to the specification.

Applicants have amended the specification to include sequence identifiers for the sequence listing being submitted simultaneously herewith. As such, this amendment includes no new matter and its entry is respectfully submitted.

In view of the foregoing, applicant respectfully submits that all claims are in condition for allowance. Early and favorable action is requested.

In the event that any additional fees are required, the PTO is authorized to charge our deposit account No. 50-0850.

Respectfully submitted,

Date: 5/22/02

Ronald I. Eisenstein

(Reg. No.: 30,628)

NIXON PEABODY LLP

101 Federal Street Boston, MA 02110 (617) 345-6054